CORDIS
EU research results

CORDIS

English EN

Repair of tissue and organ damage in refractory chronic graft versus host disease after hematopoietic stem cell transplantation by the infusion of purified allogeneic donor regulatory T lymphocytes

Project information

Grant agreement ID: 643776

Status

Closed project

  • Start date

    1 January 2015

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 899 250

  • EU contribution

    € 5 899 250

Coordinated by:

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal

Objective

Our proposal encompasses parallel clinical trials addressing the feasibility and the effectiveness of donor-derived regulatory T cells (Treg) as a therapeutic agent in the treatment and prevention of tissue and organ damage resulting from graft versus host disease (GVHD) after hematopoietic stem cell transplantation (HSCT).
We propose a collaborative clinical study in which Treg therapy for GHVD is the common dominator. However, by bringing together several clinical centers with expertise in this area, we are also having the opportunity to simultaneously address other issues that would not otherwise be addressable by each clinical center on its own. Firstly, by using different Treg preparation strategies, we will be able to determine whether ex vivo isolated Treg are sufficient or whether in vitro expansion and subsequently higher dosages are required. Secondly, we will investigate if sole Treg infusion is effective or if rather co-administration of therapeutic agents that are likely to induce Treg survival and expansion in vivo (rapamycin; IL-2) is required for a successful response to Treg therapy.
The studies on GVHD treatment outcome will be pursued together with a detailed analysis of immune monitoring, comprising T cell receptor clonotype tracking and tissue regeneration markers, in order to further understand the mechanisms underlying the therapeutic and regenerative potential of Treg cells.
Our consortium has developed a concerted approach to the topic of Treg therapy in GVHD. This is a unique opportunity to determine the validity of this cellular immunotherapy approach in GVHD prevention and treatment, with potential for a significant impact on patient quality of life, survival rate and ultimately on the quality of health care provided.

Coordinator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Address

Avenida Prof Egas Moniz
1649 028 Lisboa

Portugal

Activity type

Research Organisations

EU Contribution

€ 1 792 894,46

Participants (8)

KLINIKUM DER UNIVERSITAET REGENSBURG

Germany

EU Contribution

€ 1 348 823,75

UNIVERSITE DE LIEGE

Belgium

EU Contribution

€ 496 200

AZIENDA OSPEDALIERO UNIVERSITARIA POLICLINICO S. ORSOLA MALPIGHI

Italy

EU Contribution

€ 617 080

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 741 335

ALACRIS THERANOSTICS GMBH

Germany

EU Contribution

€ 277 500

THE UNIVERSITY OF LIVERPOOL

United Kingdom

EU Contribution

€ 246 077,50

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 88 919,29

SERVICIO ANDALUZ DE SALUD

Spain

EU Contribution

€ 290 420

Project information

Grant agreement ID: 643776

Status

Closed project

  • Start date

    1 January 2015

  • End date

    31 December 2019

Funded under:

H2020-EU.3.1.3.

  • Overall budget:

    € 5 899 250

  • EU contribution

    € 5 899 250

Coordinated by:

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal